Tagrisso, Imfinzi, Truqap, and Enhertu all reported double-digit sales growth during the fourth quarter and full-year 2025 ...

The firm will test the FSHR-targeting lira-cel at up to 100-tmes higher doses after seeing better than expected outcomes at ...

NEW YORK – Yatiri Bio's artificial intelligence-based proteomic platform is giving new hope to a SMARCA2/4 inhibitor program that Foghorn Therapeutics previously halted. After seeing Yatiri's ability ...

The FDA raised concerns about multiple facets of the study protocol used to evaluate RGX-121, including the eligibility criteria and surrogate endpoints.

It is the first CAR-T that the agency has said is safe for this hard-to-treat subset of lymphoma patients based on data from an investigator-initiated study.

NEW YORK – Eli Lilly on Monday said it will acquire in vivo CAR T-cell therapy developer Orna Therapeutics to strengthen its R&D work in genetic medicine and in vivo cell engineering.

Biogen's "growth products" — about a half-dozen products including Leqembi — contributed $800 million to the firm's $2.28 ...

GT Biopharma is set to begin a Phase I trial in mid-2026 of its B7-H3-targeting natural killer cell engager, after the US Food and Drug Administration cleared its investigational new drug application ...

Long-term data on four patients' who had received avigbagene parvec gave the firm confidence to advance a late-stage single-arm trial that can support regulatory approval.

"All healthcare providers should be aware of the risks of DPD deficiency," inform patients of toxicity risks, and test patients unless treatment is immediately needed, the agency said.

This year, the firm will focus on commercializing and further developing the ovarian cancer drug and discuss the registrational path with the FDA for a KRAS G12D inhibitor.